In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews medical oncologist Dr. Andrea Apolo from the National Cancer Institute, USA, on the results of the AMBASSADOR study, which she presented at ASCO GU24.
Dr. Apolo shares details on the rationale of the AMBASSADOR study: An open-label, randomised, phase III trial, evaluating the efficacy and safety of pembrolizumab as an adjuvant treatment in muscle-invasive and locally advanced urothelial carcinoma (MIUC).
Dr. Apolo discusses the positive second interim data for disease-free survival (DFS), with a medium DFS with adjuvant pembrolizumab of 29 months vs. 14 months in the observation arm. Based on these findings, Dr. Apolo stated that pembrolizumab is active and should be considered as a therapy for patients in the adjuvant setting.
For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.